Ladenburg Thalmann to hold an analyst/industry conference call

Managing Director-Equity Research Cohen, along with Dr. Charalampos Tzoulis, Neurology & Neurogenetics Professor at the University of Bergen & Haukeland University Hospital in Bergen Norway, provide a detailed review of the impact ChromaDex’s product, Tru Niagen, has had in various studies on an Analyst/Industry conference call to be held on February 7 at 10 am. Webcast Link

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on CDXC:

• ChromaDex shares findings of CMAs with NR improved cognition in Alzheimer’s
• ChromaDex announces findings from study on proprietary Niagen ingredient
• ChromaDex appointed Bohr to its SAB
• ChromaDex appoints Brianna Gerber as CFO
• ChromaDex: NR supplementation significantly increased NAD+ levels in NEVs